Skip to main content
. 2021 Sep 29;10(19):4512. doi: 10.3390/jcm10194512

Figure 3.

Figure 3

The value of bio-ADM at inclusion (boxplots) in (A) patients with or without refractory cardiogenic shock, (B) patients with or without arrhythmias (i.e., comprised ventricular tachycardia, ventricular fibrillation, atrial fibrillation), and (C) patients with or without mechanical circulatory support implementation. Dots indicate outliers. bio-ADM, bioactive adrenomedullin; CS, cardiogenic shock; MCS, mechanical circulatory support.